Clinical trials: Drug Removal
Acute Pain
Nefopam/Paracetamol Fixed Dose Combination in Acute Pain After Impacted Third Molar Extraction
This study aims to evaluate the analgesic efficacy of single and multiple doses of a new fixed dose combination of nefopam hydrochloride 30 mg and paracetamol 500mg taken orally in comparison to each single component.
- Trial name
- NCT04622735
- Testing
- nefopam hydrochloride 30mg / paracetamol 500mg X2, Paracetamol 500 Mg Oral Tablet X2, Nefopam HCl 30 MG Oral Tablet X2
- Where
- 19 sites in Belgium, France and 3 more
- Volunteers
- 321 people
- Sponsor
- Unither Pharmaceuticals, France
Anesthesia
Improving Information Extraction From EEG on Cerebral Anesthetic Drug Effects
This is an interventional, randomized controlled study in health volunteers that involves collecting data on raw EEG waves measuring various combinations of anesthetic drugs during standardized drug titration.
- Trial name
- NCT02043938
- Testing
- SedLine EEG sensor
- Where
- Netherlands
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Masimo Corporation
Cerumen Impaction of Both Ears
Evaluation of a Novel Product for the Removal of Impacted Human Cerumen (Earwax)
This is a prospective, open-labeled clinical trial. Subjects that qualify for enrollment and provide informed consent will be treated with a novel topical cerumen (earwax) removal product.
- Trial name
- NCT02829294
- Testing
- E002 - cerumen removal aid
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Dr. Joseph Griffin
Radiographic Contrast Agent Nephropathy
Contrast Media Reduction and Removal in Patients With Chronic Kidney Disease (CKD) (PRESERV)
The purpose of this clinical trial is to demonstrate the efficacy and safety of the Osprey Medical CINCOR™ Contrast Removal System.
- Trial name
- NCT01168024
- Testing
- CINCOR™ System and contrast conservation unit (CCS-1), Standard of Care plus peri-procedural hydration
- Where
- 21 sites in United States, Germany
- Volunteers
- 16 people
- Sponsor
- Osprey Medical, Inc
Breast Cancer
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
The study will evaluate the effectiveness of ixabepilone when given after doxorubicin plus cyclophosphamide (AC) compared to standard treatment of paclitaxel given after doxorubicin plus cyclophosphamide in patients with early…
- Trial name
- NCT00455533
- Testing
- Ixabepilone, Paclitaxel, Cyclophosphamide
- Where
- 49 sites in United States, Argentina and 13 more
- Volunteers
- 384 people
- Sponsor
- Bristol-Myers Squibb
Non-small Cell Lung Cancer
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
This is a study to evaluate the effectiveness of erlotinib compared with a placebo sugar pill following complete surgical removal of the tumor with or without chemotherapy after surgery in Stage IB-IIIA NSCLC patients.
- Trial name
- RADIANT (NCT00373425)
- Testing
- Erlotinib
- Where
- 295 sites in United States, Argentina and 17 more
- Volunteers
- 1,252 people
- Sponsor
- OSI Pharmaceuticals
Hemorrhage, Surgical, Blood Loss, Surgical
Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T)
Prospective, multi-center, double-blind, randomized pivotal trial to evaluate the safety and effectiveness of the DrugSorb-Antithrombotic Removal (ATR) system for intraoperative removal of ticagrelor in patients undergoing urgent…
- Conditions
- Hemorrhage, Surgical, Blood Loss, Surgical, Blood Loss, Postoperative, Hemorrhage Postoperative
- Trial name
- STAR-T (NCT04976530)
- Testing
- DrugSorb-ATR system
- Where
- 29 sites in United States, Canada
- Volunteers
- 140 people
- Sponsor
- CytoSorbents, Inc
Emergent Cardiothoracic Surgery, Bleeding
Ticagrelor CytoSorb Hemoadsorption
TISORB is a study to show that the CytoSorb device removes ticagrelor from blood during surgery in patients who need emergency surgery on their heart.
- Conditions
- Emergent Cardiothoracic Surgery, Bleeding, Drug Removal
- Trial name
- TISORB (NCT04131959)
- Testing
- CytoSorb 300 mL device
- Where
- 8 sites in United Kingdom
- Volunteers
- 5 people
- Sponsor
- CytoSorbents, Inc
End Stage Renal Disease Requiring Hemodialysis
Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug
Patients whose kidneys are no longer able to work as they should and require treatment to filter wastes from the blood (hemodialysis) are at high risk for blood clots that form in blood vessels (thrombosis) blocking blood flow…
- Trial name
- RE-THINc ESRD (NCT04534114)
- Testing
- Fesomersen sodium (BAY2976217)
- Where
- 69 sites in United States, Belgium and 13 more
- Volunteers
- 307 people
- Sponsor
- Bayer
Postoperative Gastrointestinal Dysfunction
A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery
The main aim of this study is to check for side effects from TAK-954 and whether it speeds up the recovery of gastrointestinal function after small-bowel or large-bowel resection surgery.
- Trial name
- NCT03827655
- Testing
- TAK-954
- Where
- 25 sites in United States, Germany
- Volunteers
- 209 people
- Sponsor
- Takeda
Post-surgical Pain Following Extraction of Molar Teeth
A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain
This is a randomized, double blind, placebo-controlled, parallel group, single-center study in approximately 560 subjects to determine the overall analgesic efficacy and safety of a fixed-dose ibuprofen 250 mg / acetaminophen 500…
- Trial name
- SDDP (NCT02912650)
- Testing
- Ibuprofen 250 mg / Acetaminophen 500 mg, Ibuprofen 250 mg, Acetaminophen 650 mg
- Where
- United States
- Volunteers
- 568 people
- Sponsor
- Pfizer
Scar Prevention, Scar Reduction
A Study to Evaluate the Safety and Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloid Scars
The purpose of this study was to determine the safety of AZX100 Drug Product and to determine whether it was effective in preventing or reducing re-growth of surgically removed keloid scars.
- Trial name
- NCT00892723
- Testing
- AZX100 Drug Product
- Where
- 3 sites in United States
- Volunteers
- 59 people
- Sponsor
- Capstone Therapeutics
Scar Prevention, Scar Reduction
A Study to Evaluate the Safety and Efficacy of AZX100 Drug Product Following Excision of Keloid Scars
The purpose of this study was to determine the safety of AZX100 Drug Product and to determine whether it was effective in preventing or reducing re-growth of surgically removed keloid scars.
- Trial name
- NCT00825916
- Testing
- AZX100 Drug Product
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- Capstone Therapeutics
Acute Pain
Tramadol Hydrochloride and Dexketoprofen Trometamol for the Oral Treatment of Moderate to Severe Acute Pain Following Removal of Impacted Lower Third Molar
The study is aimed to evaluate the analgesic efficacy of TRAM.HCl/DKP.TRIS 75mg/25mg oral fixed drug combination in comparison with TRAM.HCl /paracetamol 75mg/650mg in the treatment of moderate to severe acute pain.
- Trial name
- DAVID (NCT02777970)
- Testing
- Tramadol Hydrochloride/Dexketoprofen Trometamol, Tramadol Hydrochloride/Paracetamol
- Where
- 18 sites in Hungary, Italy and 3 more
- Volunteers
- 654 people
- Sponsor
- Menarini Group
HER2-positive Breast Cancer, Early-stage Breast Cancer
Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03
This is an extension study to provide adjuvant treatment with single agent Herceptin or TX05 and assess continued safety and immunogenicity in subjects with HER2-positive early breast cancer following neoadjuvant treatment and…
- Conditions
- HER2-positive Breast Cancer, Early-stage Breast Cancer, Breast Cancer, Breast Neoplasms
- Trial name
- NCT04109391
- Testing
- TX05 (trastuzumab), Herceptin (trastuzumab)
- Where
- 86 sites in Belarus, Chile and 8 more
- Volunteers
- 338 people
- Sponsor
- Tanvex BioPharma USA, Inc.